Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Lung Neoplasms 1 Liver Neoplasms 1 Leukemia, Myelomonocytic, Chronic 1 Kidney Neoplasms 1 Hodgkin Disease 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Endocrine Gland Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Intraductal, Noninfiltrating 1 Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 96 Carboplatin 67 Paclitaxel 56 Cyclophosphamide 40 Capecitabine 30 Specimen Handling 28 sacituzumab govitecan 25 130-nm albumin-bound paclitaxel 24 Gemcitabine 22 Magnetic Resonance Spectroscopy 21 Doxorubicin 20 olaparib 19 Taxes 19 Biopsy 19 Albumin-Bound Paclitaxel 19 Drug Therapy 16 atezolizumab 13 Nivolumab 13 toripalimab 12 Radiotherapy 12 Epirubicin 12 durvalumab 11 Docetaxel 10 Cisplatin 10 Bevacizumab 10 eribulin 9 fludarabine 8 Standard of Care 7 Radiation 7 Injections 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Triple Negative Breast Neoplasms × Biopsy, Large-Core Needle × 1 year × Clear all

NCT05435352 2025-07-30

PEAR-TNBC

Ourotech, Inc.

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡